REPLIGEN CORP

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems designed to increase efficiencies and flexibility in manufacturing biological drugs. The company's primary customers are global biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies (integrators) that face pressures related to production cost, capacity, quality, and time. Repligen's products are used in the production of critical biologic drugs, including monoclonal antibodies (mAbs) and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines, and cell and gene therapies (C&GT). The company operates as one bioprocessing business, offering a comprehensive suite of products for both upstream and downstream processes in biological drug manufacturing. With over 40 years of industry expertise, Repligen has developed a broad and diversified product portfolio. The company pursues growth through internal innovation, commercial leverage, and targeted acquisitions. Repligen's corporate headquarters are in Waltham, Massachusetts, with additional administrative and manufacturing operations located worldwide.